Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05745714
Title HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART C)
Acronym HEM-iSMART C
Recruitment Not yet recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Princess Maxima Center for Pediatric Oncology
Indications
Therapies
Age Groups: adult | child
Covered Countries NLD

Facility Status City State Zip Country Details
Princess Máxima Center for Pediatric Oncology Utrecht 3584CS Netherlands Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field